by Zachary Stieber and Jan Jekielek
A recently published study (Ivermectin Prophylaxis used for COVID-19) indicating the anti-parasitic Ivermectin worked well as a prophylactic against the virus that causes COVID-19 should help sway critics of the drug, according to Dr. Pierre Kory, president of the Front Line COVID-19 Critical Care Alliance (FLCCC).
The Brazilian city of Itajaí launched a program that gave Ivermectin to any residents that wanted any.
The period that was studied was from July 7, 2020, to December 2, 2020. Researchers found that the program, which had over 100,000 residents participate, was linked to a 44 percent drop in COVID-19 cases...
Approximately 3.7 percent of Ivermectin users contracted the illness during the trial period, compared to 6.6 percent of residents who didn't take the drug.
The program was also associated with a statistically significant decrease in hospitalization and mortality.
The peer-reviewed study was published in Cureus on Jan. 15.
FLCCC focuses on early treatment of COVID-19, the disease caused by the CCP (Chinese Communist Party) virus. The group has recommended Ivermectin since early 2020.
Kory said the lack of reporting on the study despite it being peer-reviewed highlights how some scientific developments are ignored by many media outlets and scientists.
A woman holds a box of Ivermectin
in Brasilia, Brazil in a file image.
(Andressa Anholete/Getty Images)
Studies on Ivermectin against COVID-19 have shown mixed results, with some being associated with no or little benefit and others suggesting a strong benefit.
It's been widely used in India and other countries as a preventative measure, but in the United States and much of Europe many official health care bodies recommend against its use or do not endorse it.
Ivermectin has been approved for certain uses by the Food and Drug Administration, but not for use against COVID-19. That means doctors can prescribe it off-label.
The National Institutes of Health's COVID-19 treatment guidelines panel currently says that there is not enough evidence to advise either for or against using Ivermectin to treat COVID-19.
It does not address its potential use as a prophylactic.
While the new study was celebrated by some, others questioned the findings and pointed out that the conflicts of interest disclosures show both Cadegiani and another author have received funding from or contracted with Vitamedic Industria Farmaceutica, a company that manufactures Ivermectin.
Gideon Meyerowitz-Katz, an Australian epidemiologist, for instance, called it,
Cadegiani said the criticism was unfounded, saying he wasn't convinced before the study that Ivermectin would work as a preventative medicine and that researchers controlled for "all relevant factors," including co-morbidities, age, sex, and race.
The researchers plan on publishing multiple additional papers regarding the program, including papers on the biochemical effects of Ivermectin and the effectiveness of the drug in preventing hospitalization...
Dr. Pierre Kory
The War on Hydroxychloroquine, Ivermectin, and Other Cheap Drugs to Treat COVID-19
"We live in a system that favors high-profit medicines.
Those are the only things in play, and they don't work.
They are failing," says Dr. Pierre Kory,
a pulmonary and critical care specialist.
president of the Frontline COVID-19 Critical Care Alliance.
why haven't there been more clinical trials
repurposed drugs to treat COVID-19?
It's about the pharmaceutical industry capture of our agencies,
and how our policies are all directed
at suppressing and avoiding"
the use of cheap, repurposed drugs, says Kory.